Amylyx Resets As A Clinical-Stage Company, Withdrawing Relyvrio
Workforce Will Be Cut By 70%
The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.
The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.